Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research
  • Published:

Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events

International Journal of Impotence Research volume 16, pages S34–S37 (2004)Cite this article

Abstract

Vardenafil potently inhibits human phosphodiesterase 5 (PDE5) with an IC50 of 0.7 nM. Enhancement of nitric oxide (NO)-induced erections in rabbits by 0.1 mg/kg vardenafil is limited by its pharmacokinetic properties (Tmax=1 h; T1/2=1.2 h), although erectile effects have been observed after 7 h. In humans, vardenafil is rapidly absorbed (Tmax ≈40 min) and more slowly metabolized (T1/2≈4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil). Although the consumption of high-fat meals does not affect the drug’s relative bioavailability, it retards intestinal absorption. Coadministration of CYP3A4 inhibitors such as ritonavir can affect hepatic metabolism. M1, an active metabolite of vardenafil, is a four-fold-less potent inhibitor of PDE5 than its parent compound, contributing approximately 7% to vardenafil’s overall efficacy. The side effects of all selective PDE5 inhibitors commonly include vasodilation, small reductions in blood pressure, headache, and nasal congestion.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Saenz de Tejada I et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282–290.

    Article  CAS  Google Scholar 

  2. Choi S et al. Efficacy of vardenafil and sildenafil in facilitating penile erection in an animal model. J Androl 2002; 23: 332–337.

    CAS  PubMed  Google Scholar 

  3. Bischoff E et al. The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model. J Urol 2001; 165: 1316–1318.

    Article  CAS  Google Scholar 

  4. Giuliano F et al. Proerectile effect of vardenafil: in vitro experiments in rabbits and in vivo comparison with sildenafil in rats. Eur Urol 2003; 44: 731–736.

    Article  CAS  Google Scholar 

  5. Klotz T et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19: 32–39.

    Article  CAS  Google Scholar 

  6. Bischoff E et al. Vardenafil improved erection at four times the plasma half life in a conscious rabbit model. Int J Impot Res 2002; 14(Suppl 3): S42.

    Google Scholar 

  7. Wallis RM, Corbin JD, Francis SH, Ellis P . Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83(5A): 3C–12C.

    Article  CAS  Google Scholar 

  8. Rehse K, Scheffler H, Reitner N . Interaction of Viagra with the NO donors molsidomine and RE 2047 with regard to antithrombotic and blood pressure-lowering activities. Arch Pharm (Weinheim) 1999; 332: 182–184.

    Article  CAS  Google Scholar 

  9. Berkels R et al. Modulation of human platelet aggregation by the phosphodiesterase type 5-inhibitor sildenafil. J Cardiovasc Pharmacol 2001; 37: 413–421.

    Article  CAS  Google Scholar 

  10. Prickaerts J et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 2002; 113: 351–361.

    Article  CAS  Google Scholar 

  11. Baratti CM, Boccia MM . Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. Behav Pharmacol 1999; 10: 731–737.

    Article  CAS  Google Scholar 

  12. Schultheiss D et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J Urol 2001; 19: 46–50.

    Article  CAS  Google Scholar 

  13. Hoheisel U, Unger T, Mense S . A block of spinal nitric oxide synthesis leads to increased background activity predominantly in nociceptive dorsal horn neurones in the rat. Pain 2000; 88: 249–257.

    Article  CAS  Google Scholar 

  14. Asomoza-Espinosa R et al. Sildenafil increases diclofenac antinociception in the formalin test. Eur J Pharmacol 2001; 418: 195–200.

    Article  CAS  Google Scholar 

  15. Dundar M, Kocak I, Dundar SO, Erol H . Evaluation of side effects of sildenafil in a group of young healthy volunteers. Int Urol Nephrol 2001; 32: 705–708.

    Article  CAS  Google Scholar 

  16. Fink HA et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002; 162: 1349–1360.

    Article  CAS  Google Scholar 

  17. Kruuse C, Thomsen LL, Jacobsen TB, Olesen J . The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab 2002; 22: 1124–1131.

    Article  CAS  Google Scholar 

  18. Zhang R et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 2002; 33: 2675–2680.

    Article  CAS  Google Scholar 

  19. Cellek S, Rees RW, Kalsi J . A Rho-kinase inhibitor, soluble guanylate cyclase activator and NO-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. Expert Opin Investig Drugs 2002; 11: 1563–1573.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bayer Pharma Research, Bayer Healthcare Wuppertal, PH-R-EU-CV-ll, Wuppertal, Germany

    E Bischoff

Authors
  1. E Bischoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Bischoff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bischoff, E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res 16 (Suppl 1), S34–S37 (2004). https://doi.org/10.1038/sj.ijir.3901213

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901213

Keywords

This article is cited by

Search

Advanced search

Quick links